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ABSTRACT
The period of immunodeficiency following autologous hematopoietic stem cell transplantation is characterized by
transient expansions of CD8CD45ROCD57 T lymphocytes, displaying markers of an activated phenotype.
Most evidence suggests that this early reconstitution results from proliferation of mature T cells that have survived
conditioning or were transferred with the graft. Although homeostatic mechanisms are thought to act in maintaining
total T-cell numbers, the degree to which antigen-driven expansions contribute and the nature of the stimulating
antigens remain unclear. CD34 selection of stem cell grafts reduces the available T-cell pool, potentially delaying
immune reconstitution and resulting in increased infective complications. In the allogeneic transplantation setting,
lymphopenia has been associated with cytomegalovirus (CMV) infection risk and, if persistent, with adverse outcome.
We prospectively studied patients undergoing CD34-selected (n  13) or unselected (n  13) autologous hemato-
poeitic stem cell transplantation for immune reconstitution and CMV infection. No significant differences were
demonstrated between graft types with respect to lymphocyte subset recovery, T-cell receptor -chain variable
region spectratype diversity, or CMV DNA detection rates (45% versus 40%). CMV infection was associated with a
trend toward higher rather than lower CD8 counts at 6 weeks posttransplantation (P .08) that became significant
by 3 months (P .007), and that was associated with decreased T-cell receptor -chain variable region spectratype
diversity (P  .01). CMV-specific HLA-tetramer analysis demonstrated transient expansions with CDR3 lengths
corresponding to those of some of the major posttransplantation T-cell expansions demonstrated by spectratype
analysis suggesting that CMV-specific T cells contribute to the pattern of immune reconstitution.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Myeloablative chemotherapy supported by autologous he-
matopoietic stem cell transplantation (HSCT) is accepted by
many physicians as the standard of care for newly diagnosed
patients with multiple myeloma younger than 65 to 70 years of
age. This approach improves both event-free and overall sur-
vival compared with standard-dose chemotherapy alone as dem-
onstrated in a randomized trial reported by the Intergroupe
Francais du Myelome [1,2]. However, the elimination of endog-
enous hematopoietic stem cells (HSCs) and progenitor cells
along with signiﬁcant numbers of mature white blood cells
results in major, and in some cases prolonged, perturbations in
immune response. Although early recovery of innate immunity
(myeloid series and natural killer cells) results in reconstitution
of protective immunity against many bacterial pathogens, both
the absolute levels and function of T and B lymphocytes remain
abnormal for many months, resulting in prolonged susceptibility
to viral pathogens [3,4].
The reconstituting T-cell repertoire appears to be derived
of cells from a number of sources. Contributions are made in
varying proportions from expansions of infused mature lympho-
cytes, of residual T lymphocytes that have survived the condi-
tioning therapy, and from the development of thymic-indepen-
dent and thymic-dependent naive T cells [3]. The reduced
thymic function that characterizes immune reconstitution in
adults as compared with children results in a smaller contribu-
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tion of HSC-derived T-cells and lower numbers of CD45RA
as compared with CD45RO T cells. The development of the
T-cell receptor excision circlet assay has conﬁrmed the relatively
low levels of circulating cells in adults post-HSCT that derive
from T cells with newly arranged T-cell receptors (ie, HSC-
derived), although it has demonstrated that these pathways are
to some degree active in adults and that the balance of T-
lymphocyte reconstitution may be inﬂuenced by the progenitor
cell content of the graft [5-7]. T-cell receptor excision circlet
levels were higher in patients who received CD34-selected com-
pared with those who received unselected grafts [6]. Enrichment
for cells bearing the CD34 antigen is an effective method of
reducing tumor cell contamination of the graft in patients un-
dergoing HSCT for myeloma. It has not, however, resulted in
improved outcome [2,8]. One of the possible explanations for
this is that effects on immune reconstitution, perhaps related to
the signiﬁcant reduction in the number of mature T lympho-
cytes infused along with the HSCs in the CD34-selected setting,
result in an increase in infective complications [9-11].
Previous reports comparing T-lymphocyte subset reconsti-
tution according to graft type following autologous HSCT have
produced differing results. Although some found signiﬁcant
delays in the reconstitution of lymphocyte subsets following
CD34 selection [12-14], interpretation is complicated in many
by the lack of a control group [12] or by the lack of an indication
as to why one group received CD34-selected and the other
received unselected grafts [13]. In addition, heterogeneity of
patient diagnoses and prior therapies may impact on lymphocyte
number or function at the time of harvesting. A common feature
of most studies is a persistently low CD4 lymphocyte count
following transplantation, and this is the feature that is most
often reported to be signiﬁcantly lower in the CD34-selected
cohort. The low CD4 T-cell numbers occur despite a rela-
tively rapid expansion in T lymphocytes in the weeks following
transplantation (due mainly to increases in CD8 T-cell num-
bers with an attendant prolonged inversion of the CD4:CD8
ratio). Given that a large proportion of the early increase in
lymphocytes is likely to derive from expansion of mature cells, it
has been suggested that CD34 selection may result in an in-
creased susceptibility to infection in part because of a reduction
in the number of clonotypes available in the reduced T-cell
pool.
To address these issues, a prospective study on 26 patients
with myeloma undergoing autologous HSCT with either
CD34-selected or -unselected grafts was undertaken. Cytomeg-
alovirus (CMV) infection was used as a surrogate marker of
T-cell function to ascertain whether there was an increased
incidence following CD34 selection and whether this correlated
with reconstitution of lymphocyte subsets or T-cell receptor
-chain variable region (TCRBV) spectratypes. Analysis with
CMV-speciﬁc HLA-tetramers and TCRBV spectratyping al-




Patient characteristics are outlined in Table 1. The institu-
tional Ethics Committee approved the study protocol, and in-
formed consent was obtained. All received peripheral blood
stem cell grafts. CD34 selection was performed using either the
Ceprate (Cellpro, Seattle, WA) (n  6), Isolex 300i (Baxter
Healthcare, Deerﬁeld, IL) (n  1), or CliniMACS (Miltenyi
Biotech GmbH, Bergisch Gladback, Germany) (n  6) sorting
device. The absolute T-cell count (105 CD3 cells) in the
CD34-puriﬁed fraction according to prior departmental expe-
rience was 72 (range, 54 to 184), 25 (range, 10 to 184), and 0.3
(range, 0.2 to 31), respectively, corresponding to 3, 3.6, and 5.7
logs of T-cell depletion. The control group was provided by
consecutive patients resulting from a change in departmental
policy following the publication of studies suggesting a lack of
clinical beneﬁt associated with CD34 selection. The CMV
serostatus of the patients was determined before transplantation
using a complement ﬁxation test (in-house test, using CMV
strain AD169 as antigen; positive if titer 1:5 or greater) and
gelatin particle agglutination assay (Serodia, Fujirebio Inc., To-
kyo, Japan; positive if titer 1:8 or greater). In cases of discrepant
results, an enzyme immunoassay (Vidas CMV immunoglobulin
G, bioMerieux, Marcy-l’Etoile, France; positive if at least 6
arbitrary units/mL) was performed as a third test and the results
of the 2 concordant tests were used. CMV-seropositive patients
received blood components unscreened for CMV. CMV-sero-
negative patients received blood components from CMV-sero-
negative donors. Oral aciclovir prophylaxis was administered
(200 mg 3 times daily) from admission until at least 3 months
posttransplantation or until the CD4 count was 0.2  109/L.
There were no signiﬁcant differences between the docu-
mented characteristics of the CD34-selected and -unselected
cohorts other than the increased number of patients receiving
total body irradiation (TBI) as part of the conditioning regimen
in the CD34-selected group (P  .02; Fisher exact test).
Immunophenotyping and TCRBV Analysis
Cell surface immunophenotypic analysis was performed on
peripheral blood mononuclear cells (PBMCs) with PC5-conju-
gated anti-CD3, FITC-conjugated anti-CD8, and RD1-conju-
gated anti-CD4 monoclonal antibodies (Cyto-Stat trichrome,
BeckmanCoulter, High Wycombe, United Kingdom). Aliquots





Median age (range) 51 (40-62) 52 (46-61)




Light chain 1 2
Non-secretory/POEMS 1/1 1
Prior chemotherapy
No. of regimens (1/2) 12/1 10/3
Prior radiotherapy (local) 2 3
CMV serostatus (positive/
negative) 11/2 10/3
Median CD34 dose (106




POEMS indicates polyneuropathy, organomegaly, endocrinopathy,
monoclonal gammopathy, skin changes.
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of 100 L containing 1  106 cells were stained at 4oC for 30
minutes, washed, and then ﬁxed in a ﬁnal concentration of 2%
paraformaldehyde. The stained and ﬁxed samples were analyzed
in a ﬂow cytometer (BeckmanCoulter). List mode ﬁles of 40000
to 50000 events were acquired. The numbers of each phenotyp-
ically deﬁned cell type in the peripheral blood per microliter was
determined by multiplying the numbers of lymphocytes per
microliter by the percentage of nucleated cells with that pheno-
type that fell within the lymphocyte gate, as determined using
ﬂow cytometry.
TCRBV spectratyping was performed as previously de-
scribed on complementary DNA (cDNA) generated from the
RNA extracted from PBMCs isolated from heparinized blood by
gradient centrifugation through Ficoll-Paque (Pharmacia, St.
Albans, United Kingdom). TCRBV gene subfamilies were am-
pliﬁed across the CDR3-encoding regions using 23 BV subfam-
ily-speciﬁc primers [15] and a ﬂuorescent dye-conjugated (FAM,
Perkin Elmer, Cambridge, United Kingdom) BC region-spe-
ciﬁc primer. Hot start polymerase chain reaction (PCR) ampli-
ﬁcations were performed in a total volume of 20 l containing
Genamp PCR buffer (Perkin Elmer), 2mM MgCl2, 0.2 mM
each dNTP, 1 mM of each primer and 1l cDNA. In the case
of the cells sorted according to dual staining with CD8 mono-
clonal antibody and tetrameric complex the total cDNA was
divided equally between the PCR reactions. After a 5-minute
denaturation step at 95° C for 30 seconds, 0.5 U of Amplitaq
DNA polymerase (Perkin Elmer) were added. Optimal cycling
conditions were 95oC for 30 seconds, 58oC for 30 seconds, and
72oC for 45 seconds, for 30 cycles, followed by a ﬁnal extension
at 72oC for 5 minutes. Next, 1 L of PCR product was dena-
tured in 12 L of formamide and electrophoresed through
Performance Optimized Polymer 4 (Perkin Elmer) on an ABI
110 automated sequencer (Perkin Elmer) in the presence of
Tamra 500 size standard (Perkin Elmer). Genescan software 2.1
(Perkin Elmer) was used to analyze the data. Following transla-
tion of spectratype proﬁle data into a probability function (based
on representation of peak area as a percentage of total peak area
for each family proﬁle), data were analyzed according to the
previously described diversity scoring system designed to recog-
nise multiple characteristics of the histogram proﬁles (oligo-
clonal peaks, total peak number, and skewness/kurtosis) [16].
Brieﬂy, each BV subfamily was assigned a score of 0 to 4 points
for diversity (maximum score, 23  4  92 for the complete
analysis). Using this diversity scoring system, normal adult sam-
ples scored a median of 80 (range, 69 to 86; n  12).
CMV Surveillance
DNA was extracted from whole blood in disodium edetate
using a commercial kit (Qiagen blood kit, Qiagen, Hilden,
Germany). The nested PCR ampliﬁcation and amplicon detec-
tion used were as described previously [17]. Brieﬂy, primers
were situated in the CMV major envelope glycoprotein B gene,
two rounds of ampliﬁcation were used (ﬁrst round 35 cycles,
second round 25 cycles), and detection of PCR products (150
base pairs) was by ethidium bromide-stained agarose gel elec-
trophoresis. Positive and negative controls were included in
each PCR run, consisting of a known copy number of puriﬁed
CMV DNA (Sigma, Poole, United Kingdom) and distilled wa-
ter, respectively.
Class I HLA-Tetramer Analysis
Soluble major histocompatibility complex peptide tetramers
were produced using standard approaches [18], incorporating
the HLA-A*0201 restricted NLVPMVATV epitope (amino ac-
ids 495-503 of the CMV lower matrix protein, pp65). PBMCs
were dual-stained with the HLA-A*0201 restricted CMV-spe-
ciﬁc tetrameric complex and PE Cy5-conjugated anti-CD8
monoclonal antibody (Dako, Ely, UK) in 20 to 30 L of PBS,
2% BSA, and azide for 60 minutes on ice. Cells were washed
twice in the same buffer and analyzed immediately in a ﬂow
cytometer (BeckmanCoulter). Negative controls included cells
from CMV-seronegative individuals expressing HLA-A*0201
and from CMV-seropositive individuals not expressing HLA-
A*0201. Cells demonstrating dual staining with CD8 monoclo-
nal antibody and tetrameric complex were electronically sorted
on a BeckmanCoulter EPICS Elite ﬂow cytometer and subse-
quently analyzed using TCRBV spectratyping.
Statistical Methods
Fisher exact test for categorical data and the unpaired t test
were used to compare the characteristics of different groups of
patients as detailed in the text.
RESULTS
Engraftment and Duration of Inpatient Care
In the CD34-selected group, neutrophil engraftment
(0.5 109/L) occurred at a median of 13 days (range, 10 to 16
days) and platelet engraftment (20  109/L) at a median of 14
days (range, 10 to 21 days). This did not differ signiﬁcantly from
the unselected group in whom the corresponding values were 12
days (range, 9 to 14 days) and 14 days (range, 9 to 20 days),
respectively. Similarly, there was no signiﬁcant difference in the
duration of hospital stay (median, 22 days; range, 16 to 48 days
in the CD34-selected group; median, 22 days; range, 19 to 28
days in the unselected group; P  not signiﬁcant).
Infective Complications
CMV infection occurred in 4 of 10 (40%) unselected and 5
of 11 (45%) CD34-selected CMV-seropositive patients (P 
.58, Fisher exact test, one tailed, testing the hypothesis that
infection is more common in CD34-selected cases) (Table 2).
Only 2 patients had CMV DNA detected on 2 or more consec-
utive occasions (1 CD34-selected and 1 unselected); 1 had a
fever of unknown cause and was treated with ganciclovir; the
other was treated for co-existing bacterial infection, which re-
sulted in resolution of fever coincident with viral clearance.
There were no cases of clinically apparent CMV disease. De-
tection of CMV DNA did not occur signiﬁcantly earlier in











Unselected 10 4 0
Ceprate-selected 6 3 1
CliniMACS-selected 5 2 0
*Only 1 patient with 2 consecutive PCR positive results received
ganciclovir.
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either group (P  .2, unpaired t test). In 3 of the CD34-selected
patients, CMV DNA was detected at a single time point, cor-
responding to day 30, 36, and 42 posttransplantation, respec-
tively. Viral infection was detected on 2 non-consecutive occa-
sions in a further CD34-selected transplant recipient (day 36
and day 80), and on days 12, 19, and 26 in the patient who
received ganciclovir therapy. Antiviral therapy was continued
for 2 weeks until a negative CMV PCR assay resulted. In the
unselected group viral infection was detected on days 31, 42, and
46, respectively, in the patients with a single documented epi-
sode. In the other patient, viral DNA was detected on day 43 and
50, with subsequent viral clearance occurring without antiviral
therapy.
There were no cases of proven invasive fungal infection in
this group of patients with relatively little prior therapy. Three
patients (1 unselected and 2 CD34-selected) developed derma-
tomal varicella zoster (VZV) infections following discontinua-
tion of oral aciclovir prophylaxis (Table 3). There were no
signiﬁcant differences in the rate of bacterial infections (gram-
positive or gram-negative organisms) between the two groups
(Table 3).
Immunophenotyping and TCRBV Analysis
There were no statistically signiﬁcant differences between
the CD34-selected and unselected groups with respect to total
lymphocyte, CD4 T cell, or CD8 T-cell reconstitution
(Figure 1A and Figure 1B; P  not signiﬁcant at any time point,
unpaired t test). Analysis of CD4 T-cell counts in the CMV-
seropositive patients according to CMV infection demonstrated
no signiﬁcant differences at 6 weeks posttransplantation (P 
.68, unpaired t test), but a trend toward higher counts at 3
months (P  .06, unpaired t test) and 6 months (P  .055,
unpaired t test) posttransplantation in those showing evidence of
infection (Figure 1C). There was a trend toward higher CD8






Varicella zoster—dermatomal 2 1
Bacterial
Bacteremia 2 1
Line site 1 0
Bacteremia and line site 2 2
Clostridium difficile 1 2
Figure 1. Lymphocyte subset analyses. There were no signiﬁcant correlations between (a) CD4 or (b) CD8 lymphocyte counts and CD34
selection (CD34-selected as ‚, unselected as ). CMV infection was associated with (c) a trend toward higher CD4 T-cell counts from 3 months
posttransplantation and (d) signiﬁcantly higher CD8 T-cell counts at 3 months posttransplantation (P  .007) (infection as ●, no infection as E).
Data points shown as mean /- SEM.
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T-cell counts by 6 weeks posttransplantation (P  .08, unpaired
t test) in CMV-seropositive patients with CMV infection (Fig-
ure 1C) and this difference became signiﬁcant by 3 months (P
.007, unpaired t test). By 6 months, there was no signiﬁcant
difference (P  .21, unpaired t test). Spectratype appearances
typically became less diverse following transplantation. CD34
selection had no signiﬁcant impact on spectratype diversity (P
not signiﬁcant at any time point, unpaired t test) (Figure 2A).
CMV infection, however, was associated with less TCRBV spec-
tratype diversity (Figure 2B). This was most marked at 3 months
posttransplantation (P .01, unpaired t test) coincident with the
time point at which the CD8 T-cell counts differed most
between those with and those without CMV infection. Of note,
these differences occurred following resolution of the episodes
during which CMVDNA was detected. At the earlier time point
the differences were not statistically signiﬁcant (P  .83 at 6
weeks, unpaired t test) and at later time points the differences
gradually became less pronounced (P .23 at 6 months; P .50
at 12 months, unpaired t test).
Class I HLA-Tetramer Analysis
The demonstration that patients with episodes of CMV
DNA detection may have higher CD8 T-cell counts com-
pared with those without such episodes, and that these occurred
at time points after CMV infection raised the possibility that
increasing viral load may prime these T-cell expansions. Retro-
spective analysis of stored PBMCs from 2 HLA-A*0201-positive
patients showed that CMV infection was associated with expan-
sions of CMV-speciﬁc CD8T cells in both the CD34-selected
and unselected settings (Figure 3). These CMV-speciﬁc T cells
expanded to account for 4.2% and 1.1%, respectively, of the
total CD8 T-cell population at 6 weeks posttransplantation
Figure 2. TCRBV spectratype diversity analyses. (a) CD34 selection had no signiﬁcant impact on spectratype diversity (CD34-selected as ‚,
unselected as ). (b) CMV infection was associated with less apparent TCRBV spectratype diversity, which was statistically signiﬁcant at 3 months
posttransplantation (P  .01), becoming gradually less marked during the following months (infection as ●, no infection as E). Data points shown as
mean /- SEM.
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before subsequent contraction to background levels (Figure 3).
Examination of the TCRBV spectratypes of T cells directed
toward a single HLA-restricted CMV pp65-speciﬁc epitope
(NLV) (ie, following tetramer-directed sorting) conﬁrmed that
some of the posttransplant expansions in CDR3 size peaks
corresponded in size with the CMV-speciﬁc peaks (Figure 3).
DISCUSSION
Positive selection for cells bearing the CD34 antigen results
in reduced tumor contamination of autologous grafts, but expe-
rience has differed with regard to the effect of the concurrent
lymphocyte depletion on infective complications [8,9,11,19].
The present study was not powered to detect small but signiﬁ-
cant differences in infection rates between the two groups, but
rather designed to compare lymphocyte repertoire reconstitu-
tion and attempt to correlate this with viral reactivation rates
assessed with a sensitive molecular screening assay. Although
CMV disease is uncommon following autologous HSCT, the
detection of viral infection using PCR for CMV DNA is a
relatively common event and, therefore, was used as a surrogate
marker for T-cell function. Infection rates were similar to those
in previous studies of unselected autologous HSCT [20], and
there was no evidence of an increase in those patients receiving
CD34-selected grafts. Consistent with these ﬁndings, there was
no evidence of a differential effect according to selection device
(and, hence, degree of T-cell depletion) (Table 2). These data
expand on those previously published by our group [21], but
differ from the experience of some groups indicating an in-
creased risk of CMV disease following CD34 selection [10,11].
The disparity may relate to differences in patient characteristics,
including disease diagnosis and previous and/or ongoing treat-
ments. In particular, the patients in the current study had re-
ceived relatively little prior therapy compared with those in
other studies and none received posttransplantation steroids
[9,11]. Although the patients in the current study form a rela-
tively homogeneous group, differences in conditioning therapy
(ie, inclusion of TBI in a signiﬁcant number of those with
CD34-selected grafts) do complicate interpretation. However,
TBI perhaps would be predicted to cause greater immune sup-
pression and amplify any tendency to increased infective com-
plications in the CD34-selected cohort rather than eliminate
any true differences. In the largest randomized study reported to
date including only patients with myeloma (n 190), there were
no clinically signiﬁcant differences between the 2 groups in
terms of infectious complications (either number or type) or
surrogate markers such as the number of days of hospitalization
[8,19,22].
If CD34 selection mediated an increased risk of infection by
reducing the available T-cell pool, there may be evidence of an
association between CMV infection and absolute lymphocyte
subset counts. However, there was no apparent correlation be-
tween either low CD8 or CD4 T-cell counts and CMV
infection. Indeed, if anything, there was a trend toward higher
counts during the following months in those patients with viral
DNA detection and signiﬁcantly higher CD8 T-cell counts at
3 months posttransplantation in those patients showing prior
viral infection. Coupled with the relatively short periods of
CMV DNA detection, this suggested the possibility that devel-
opment of appropriate immune responses might limit the dura-
tion of these episodes and the incidence of CMV disease in both
cohorts. A number of previous studies have documented “re-
bound” increases in CD8 T lymphocytes shortly following
transplantation. The majority of these expressed the
Figure 3. Serial TCRBV spectratype proﬁles from (a) a CD34-selected patient and (b) an unselected patient. The quantitative results of CMV-speciﬁc
HLA-tetramer analysis are shown for the same time points. Both patients had episodes of CMV infection within 6 weeks posttransplantation. The
lower panels demonstrate the spectratype proﬁles of the CMVpp65 HLA-A*0201 tetramer selected cells, demonstrating that at least some of the
CDR3 size peaks, which became more prominent following HSCT, contained CMV-speciﬁc clones.
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CD8CD45RO memory phenotype, along with CD57 and
with associated transient increases in other activation markers
[12,13,23]. This pattern of early T-cell reconstitution appears to
occur independently of the CD34 selection procedure. Also, it is
recognized that these transient T-cell expansions are oligoclonal
in both the CD34-selected and unselected setting [14,23] and
that dominant clones identiﬁed in the peripheral blood T cells
before transplantation remain predominant after transplantation
[12]. Although this would be the case if subsequent T-cell
expansions resulted from balanced expansion of all transferred
or residual mature T-cell clones, our data on CDR3 spectratype
analysis suggests that there may be a non-balanced expansion of
T-cell clones contributing to further relative increases in CDR3
size peaks, which are already demonstrated to be enlarged before
transplantation. Such peaks that skew the near-Gaussian distri-
bution of size peaks characteristic of neonatal spectratypes re-
ﬂect previous antigenic exposure. It is therefore plausible that
relative increases in peak size following transplantation could
relate to re-stimulation with the same antigens that drove the
initial clonal expansions.
There are a number of possible candidate antigens that
could drive this memory response, and it has been suggested that
at least part of the response may be directed against tumor-
derived targets [23]. Other possibilities include the multiple
epitopes of infectious agents. The herpes viruses are character-
ized by their ability to evade host immune responses and to
establish lifelong latent or persistent infections. Clinically occult
infection, as in the case of most episodes of CMV reactivation
following autologous HSCT, could potentially drive T-cell ex-
pansions sufﬁcient to re-establish control over viral replication.
The development of techniques that allow rapid and reproduc-
ible direct quantiﬁcation of antigen-speciﬁc T cells has led to
the realization that acute infections with herpes viruses are
associated with remarkably large expansions of virus-speciﬁc T
cells, which are maintained at substantially lower but still sig-
niﬁcant levels subsequently [24,25]. The current data demon-
strate that CMV infection following autologous HSCT can be
associated with appropriate expansions of CMV-speciﬁc CD8
cytotoxic T cells in both the CD34-selected and unselected
settings (Figure 3). Examination of a single HLA-restricted
CMV pp65-speciﬁc viral epitope conﬁrmed that some of the
posttransplantation expansions in CDR3 size peaks, which were
already expanded before transplantation, had identical CDR3
lengths to the CMV-speciﬁc T cells. The degree of their con-
tribution to these peaks cannot be determined from the current
data. It is possible that T cells with speciﬁcities for targets other
than CMV but that share the same CDR3 lengths also have been
expanded. However, because multiple other CMV-speciﬁc
epitopes with alternate HLA restrictions also may contribute to
the overall anti-CMV repertoire, it is possible that a signiﬁcant
proportion of the early CD8CD45RO T-cell expansion
results from re-stimulation of memory responses by an increas-
ing viral load. A similar expansion secondary to reactivation of
other herpes viruses also could contribute. Such clonal expan-
sions would be expected to subsequently reduce in size following
viral containment consistent with the pattern of decreasing
CD8 T-cell numbers during subsequent months as the risk of
viral reactivation decreases. The reduction in the percentage of
CMV pp65-speciﬁc HLA-tetramer–positive cells by 3 to 6
months posttransplantation in our patients supports this model,
as do the longitudinal analyses demonstrating relative expansion
then contraction of spectratype histogram peaks with CDR3
lengths identical to those of the CMV-speciﬁc T cells (Figure 3).
The persistently lower CD4 T-cell numbers may result partly
from quantitatively smaller clonal burst sizes, but thymic func-
tion also may be more important for reconstitution of this
compartment [3,4,6].
Our data have another important implication. Analysis of
TCRBV spectratypes following HSCT consistently shows re-
duced T-cell repertoire diversity with a subsequent gradual
return to a more diverse “normal adult” proﬁle. This has often
been equated with the abnormal immune function that charac-
terizes this posttransplantation period [14,23]. However, distor-
tion of spectratype histograms caused by appropriate clonal
expansions results in less apparent diversity, despite reﬂecting a
normal immune response. Thus our data suggests that CMV
infection may actually cause, rather than result from, reduced
spectratype diversity. Further analyses on larger numbers of
patients including HLA-tetramers with alternate epitope speci-
ﬁcities and HLA restrictions will be required to quantify the
contribution of clones with viral reactivity to the early CD8
expansions.
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